Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal spray vaccine aims to shield infants from RSV

NCT ID NCT04520659

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests a single dose of a live but weakened RSV vaccine, given as nose drops, in infants and children aged 6 to 24 months who have no prior RSV antibodies. The goal is to see if the vaccine is safe, infects the nose without causing severe illness, and triggers an immune response. Participants are monitored for side effects and antibody levels over several weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a live-attenuated RSV vaccine called LID/ΔM2-2/1030s, given as nose drops
What this could lead to
If successful, this vaccine could protect young children from severe RSV disease, reducing hospitalizations and complications.
What could go wrong
This is an early-phase trial with a small number of participants, so the vaccine may not prove effective or safe in larger studies. There is also a risk of side effects like fever or respiratory symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV INFECTION

Contacts and locations

Locations

  • John Hopkins Bloomberg School of Public Health

    Baltimore, Maryland, 21205, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

  • Vanderbilt University

    Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.